El mercado del tratamiento de la hemofilia se valoró en 12.797,36 millones de dólares en 2019 y se prevé que alcance los 20.507,92 millones de dólares en 2027; se espera que crezca a una tasa compuesta anual del 6,1 % entre 2020 y 2027.
La hemofilia es un trastorno sanguíneo genético hereditario que afecta la capacidad de la sangre para coagularse debido a la falta de una proteína particular necesaria para la coagulación de la sangre. La hemofilia se clasifica como hemofilia A, hemofilia B y C. Muchos fármacos recombinantes, como el factor antihemofílico o el factor VII, son inyectables. Los inyectables se utilizan antes de la cirugía para controlar y prevenir episodios hemorrágicos ya que el inicio de acción es rápido en comparación con otras formas. El crecimiento del mercado mundial de tratamiento de la hemofilia se atribuye a la creciente prevalencia de la hemofilia y al aumento de iniciativas gubernamentales favorables. Sin embargo, el alto costo relacionado con el tratamiento de la hemofilia es el principal factor que obstaculiza el crecimiento del mercado.
Se espera que el mercado mundial de tratamiento de la hemofilia sea testigo de un crecimiento sustancial después de la pandemia. El COVID-19 ha afectado a las economías e industrias de varios países debido a cierres, prohibiciones de viaje y cierres de empresas. La crisis de la COVID-19 ha sobrecargado los sistemas de salud pública en muchos países y ha puesto de relieve la gran necesidad de realizar inversiones sostenibles en los sistemas de salud. A medida que avanza la pandemia de COVID-19, se espera que la industria de la salud experimente una caída en su crecimiento. El segmento de ciencias biológicas prospera debido a la mayor demanda de productos de diagnóstico in vitro y al aumento de las actividades de investigación y desarrollo en todo el mundo. Sin embargo, el segmento de tecnologías médicas e imágenes está experimentando una caída en las ventas debido a un menor número de cirugías realizadas y a retrasos o prolongaciones en la adquisición de equipos. Además, se espera que las consultas virtuales realizadas por profesionales de la salud se conviertan en el modelo principal de prestación de atención después de la pandemia. Dado que la telesalud está transformando la prestación de atención, la salud digital seguirá prosperando en los próximos años. Además, también se espera que la interrupción de los ensayos clínicos y el consiguiente retraso en el lanzamiento de medicamentos allanen el camino para ensayos totalmente virtuales en el futuro. Se espera que surjan nuevas tecnologías como el ARNm y que cambien la industria farmacéutica y también se espera que el mercado sea testigo de una mayor integración vertical y empresas conjuntas en los próximos años.
regiones lucrativas para el mercado mundial de tratamiento de la hemofilia
Perspectivas del mercado< /h3>Aumento de la prevalencia de la hemofilia para impulsar el crecimiento del mercado mundial de tratamientos para la hemofilia
La hemofilia es un trastorno hemorrágico hereditario que impide que la sangre coagule normalmente. El síntoma principal es el sangrado incontrolado, a menudo espontáneo, en diferentes áreas del cuerpo. Según datos de la Fundación Nacional de Hemofilia en 2020, la hemofilia A ocurre en 1 de cada 5.000 nacimientos masculinos vivos. La hemofilia A es aproximadamente cuatro veces más común que la hemofilia B. Se prevé que el número de personas con hemofilia en los EE. UU. sea de unas 20 000 personas desde 1994. Además, la incidencia de la hemofilia no se conoce en todo el mundo; sin embargo, es probable que supere las 400.000 personas. Casi el 75% de las personas con hemofilia en todo el mundo no están diagnosticadas o reciben un tratamiento desigual.
En Italia, según datos del Centro Nacional de Información Biotecnológica (NCBI) en 2017, el número de personas registradas con hemofilia Estos trastornos aumentaron de alrededor de 7.000 en 2000 a ~8.500 en 2011, y a más de 11.000 en 2015. La tendencia se debe a un aumento en el número de pacientes registrados, principalmente aquellos con EvW tipo 1, hemofilia leve u otro factor. deficiencias.
La prevalencia de la enfermedad en los países asiáticos también está aumentando a un ritmo alarmante. Por ejemplo, según el informe de la Haemophilia Foundation Australia, 2020, más de 2800 personas fueron diagnosticadas con diversos grados de gravedad de hemofilia en el país.
Por lo tanto, el aumento de la prevalencia de la hemofilia, los elevados casos de hemofilia subdiagnosticados y la mejora de la infraestructura sanitaria impulsarán eventualmente el crecimiento del mercado para el tratamiento de la hemofilia en el período previsto.
Información basada en el producto
En términos de producto, el mercado mundial de tratamiento de la hemofilia está segmentado en concentrados de factor de coagulación derivados del plasma, concentrados de factor de coagulación recombinante, desmopresina y agentes antifibrinolíticos. . En 2019, el segmento de concentrados de factor de coagulación derivados del plasma tuvo la mayor participación del mercado. Sin embargo, se estima que el segmento de concentrados de factor de coagulación recombinante registrará la CAGR más alta durante el período de pronóstico.
Mercado global de tratamiento de hemofilia, por producto: 2019 y 2027
Perspectivas basadas en la enfermedad
El tratamiento global de la hemofilia se basa en la enfermedad El mercado está segmentado en hemofilia A, hemofilia B y hemofilia C. El segmento de hemofilia A tuvo la mayor participación de mercado en 2019. Sin embargo, se estima que el segmento de hemofilia B crecerá al ritmo más rápido durante el período de pronóstico.
Información basada en el tipo de tratamiento
Según el tipo de tratamiento, el mercado mundial de tratamiento de la hemofilia se segmenta en profilaxis y bajo demanda. El segmento de profilaxis tuvo la mayor participación de mercado en 2019. Sin embargo, se estima que el segmento bajo demanda crecerá al ritmo más rápido durante el período de pronóstico.
Terapia basada en Información útil
Basado en la terapia, el mercado mundial del tratamiento de la hemofilia se segmenta en terapia de reemplazo, terapia ITI y terapia génica. El segmento de terapia de reemplazo tuvo la mayor participación de mercado en 2019. Además, se estima que el mismo segmento registrará la CAGR más alta durante el período de pronóstico.
Información basada en el usuario final
En términos de usuario final, el mercado mundial del tratamiento de la hemofilia está segmentado en hospitales y hospitales. clínicas, centros de tratamiento de hemofilia y centros quirúrgicos ambulatorios. El segmento de hospitales y clínicas tuvo la mayor participación del mercado en 2019, y se estima que el mismo segmento crecerá al ritmo más rápido durante el período de pronóstico.
Perspectivas estratégicas
Los actores del mercado mundial del tratamiento de la hemofilia están adoptando estrategias de expansión y lanzamiento de productos para satisfacer las cambiantes demandas de los clientes en todo el mundo, lo que también les permite mantener su marca a nivel mundial.
< /p>
Mercado mundial de tratamiento de la hemofilia: por producto
- Concentrados de factor de coagulación derivado de plasma
- Factor VIII
- Factor IX
- Factor XII
- Concentrado de complejo de protrombina activado
- Factor von Willebrand
- Concentrados de factor de coagulación recombinante
- Factor VIII
- Factor IX
- Agentes antifibrinolíticos
- Desmopresina
Mercado global del tratamiento de la hemofilia: por enfermedad
- Hemofilia A
- Hemofilia B
- Hemofilia C
Mercado global de tratamiento de hemofilia: por tipo de tratamiento
- Profilaxis
- Bajo demanda
Mercado global de tratamiento de hemofilia: por Terapia
- Terapia de Reemplazo
- Terapia ITI
- Terapia Génica
Tratamiento Global de la Hemofilia Mercado: por usuario final
- Hospitales y empresas Clínicas
- Centros de tratamiento de hemofilia
- Centros de cirugía ambulatoria
Mercado global de tratamiento de hemofilia: por Geografía
- América del Norte
- Estados Unidos
- Canadá
- México
< li>Europa - Francia
- Alemania
- Italia
- Reino Unido
- España
- Resto de Europa
- Asia Pacífico (APAC)
- China
- India
- Corea del Sur
- Japón
- Australia
- Resto de APAC
- Medio Oriente y Asia África (MEA)
- Sudáfrica
- Arabia Saudita
- EAU
- Resto de MEA
- Suramérica y Centroamérica (SCAM)
- Brasil
- Argentina
- Resto de SCAM
< /ul> - Bayer AG
- Sanofi
- F . Hoffmann-la Roche Ltd.
- Kedrion SPA
- CSL Limited
- Biotest AG
- Pfizer Inc.
- Novo Nordisk A/S
- Octapharma AG
- Baxter International Inc.
Perfiles de la empresa
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The treatment of disease includes replacement therapy and gene therapy. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.
Rise in increasing prevalence of hemophilia, rise in favourable government initiatives to drive the growth of the global hemophilia treatment market during the forecast period. Moreover, growth of healthcare infrastructure among the untapped nations and increased initiatives taken up by governments are expected to fuel the growth of this market during the forecast period.
There are various type of therapy used in the treatment of hemophila disorder, such as replacement therapy, ITI therapy and gene therapy.
The List of Companies - Hemophilia Treatment Market
- Bayer AG
- Sanofi
- F. Hoffmann-la Roche Ltd.
- Kedrion S.P.A.
- CSL Limited
- Biotest AG
- Pfizer Inc.
- Novo Nordisk A/S
- Octapharma AG
- Baxter International Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Feb 2020
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2020
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Feb 2020
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Feb 2020
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2020
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2020
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Feb 2020
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Feb 2020
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)